Drug Trial Radar · NCT06714591
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
52
Actual
Start
Dec 19, 2024
Primary completion
Sep 16, 2026
Study completion Sep 16, 2026
Sponsor
- Lead sponsor
- SystImmune Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
Interventions
BL-M11D1Drug
The study includes 2 parts: Part 1 Dose escalation and Dose Finding
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants with dose-limiting toxicitiesTime frame: 1 Year
- Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)Time frame: 1 Year
- To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AMLTime frame: 1 Year
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
UCLA Ronald Reagan Medical Center
Los Angeles, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Moffitt Cancer Center
Tampa, Florida
Northwestern Memorial Hospital
Chicago, Illinois
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
START Midwest/The Cancer and Hematology Center
Grand Rapids, Michigan
John Theurer Cancer Center-Hackensack
Hackensack, New Jersey
Oncology Hematology Care Clinical Trials, LLC
Cincinnati, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
WVCI Oncology Associates of Oregon
Eugene, Oregon
Oregon Health and Science University
Portland, Oregon
Temple Health Fox Chase Cancer Center
Philadelphia, Pennsylvania
SCRI -TriStar BMT
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.